BCL2 and acute lymphoblastic leukemia: Both HMAs and the BCL-2 inhibitor venetoclax possess significant antitumor activity effects against acute myeloid leukemia/myelodysplastic syndrome and their efficacy in R/R T-ALL has been demonstrated in multiple case series [14].